Recent Price Movement and Market Context
On 20 Jan 2026, Mankind Pharma’s stock price touched Rs.2087.55, its lowest level in the past 52 weeks. This decline comes despite the stock outperforming its Pharmaceuticals & Biotechnology sector by 0.53% on the day. However, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
The broader market environment has also been challenging. The Sensex opened flat but ended the day down by 329.99 points, or 0.44%, closing at 82,877.39. The index is currently 3.96% below its 52-week high of 86,159.02 and has experienced a three-week consecutive decline, losing 3.36% over that span. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating some underlying resilience in the market.
Performance Comparison and Historical Returns
Over the last year, Mankind Pharma’s stock has generated a negative return of 21.59%, contrasting with the Sensex’s positive 7.51% gain during the same period. The stock’s 52-week high was Rs.2753.95, highlighting the extent of the recent decline. This underperformance extends beyond the short term, as the company has lagged the BSE500 index over the past three years, one year, and three months, reflecting a consistent trend of subdued returns relative to the broader market.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Financial Metrics and Profitability Trends
The company’s recent financial results have been mixed. Interest expenses for the nine months ended September 2025 stood at Rs.530.87 crore, representing a substantial increase of 122.24%. Meanwhile, the profit after tax (PAT) for the latest six-month period declined by 20.05%, amounting to Rs.949.83 crore. This contraction in profitability has contributed to the stock’s subdued performance.
Return on Capital Employed (ROCE) for the half year was recorded at 12.33%, which is relatively low compared to the company’s historical standards. The current ROCE stands at 11.7%, indicating a modest efficiency in capital utilisation. The valuation metrics show an enterprise value to capital employed ratio of 4.5, suggesting the stock is trading at a fair value relative to its peers’ historical averages, though it may be considered expensive given the recent earnings decline.
Long-Term and Near-Term Performance Assessment
Over the past year, Mankind Pharma’s profits have fallen by 17.2%, aligning with the negative stock returns. The company’s performance has been below par both in the near term and over longer horizons, as evidenced by its underperformance against the BSE500 index across multiple time frames. This trend reflects challenges in maintaining growth momentum amid competitive pressures and market dynamics.
Balance Sheet Strength and Management Efficiency
Despite the recent setbacks, the company exhibits strengths in certain areas. Management efficiency remains high, with a reported ROCE of 25.78% in other assessments, indicating effective utilisation of capital in some segments. Additionally, the company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 0.54 times, underscoring prudent financial management and a solid balance sheet position.
Institutional investors hold a significant stake of 24.59%, reflecting confidence from entities with substantial analytical resources. This level of institutional holding often provides a degree of stability in shareholding patterns, even during periods of price volatility.
Why settle for Mankind Pharma Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Ratings and Market Position
Mankind Pharma currently holds a Mojo Score of 38.0 and a Mojo Grade of Sell, reflecting a downgrade from its previous Hold rating as of 19 Nov 2025. The company’s market capitalisation grade is rated at 1, indicating a relatively modest market cap within its sector. The stock’s day change was marginally negative at -0.08%, consistent with the broader downward trend observed in recent sessions.
These ratings encapsulate the company’s current standing within the Pharmaceuticals & Biotechnology sector, highlighting the challenges it faces in regaining upward momentum amid competitive and market pressures.
Conclusion
Mankind Pharma Ltd’s stock reaching a 52-week low of Rs.2087.55 marks a notable point in its recent market journey. The decline reflects a combination of subdued profit growth, increased interest expenses, and valuation considerations, set against a backdrop of broader market weakness. While the company maintains strengths in management efficiency and debt servicing capacity, the stock’s performance over the past year and longer periods has been below benchmark indices and sector averages. This comprehensive overview provides a detailed understanding of the factors influencing the stock’s current valuation and market position.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
